ERBB2 and neoplasm: Overall, this study highlights the importance of risk-adjustment when benchmarking survival in patients with HER2-positive early-stage BC and suggests that differences in patient composition regarding clinical demographic and tumour-related factors may explain observed survival disparities between different regions.